BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saba NF, Mody MD, Tan ES, Gill HS, Rinaldo A, Takes RP, Strojan P, Hartl DM, Vermorken JB, Haigentz M Jr, Ferlito A. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy. Crit Rev Oncol Hematol 2017;115:50-8. [PMID: 28602169 DOI: 10.1016/j.critrevonc.2017.04.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Guigay J, Le Caer H, Ortholan C, Aupérin A, Michel C, Mertens C. Treatment of inoperable elderly head and neck cancer patients. Curr Opin Oncol 2019;31:152-9. [PMID: 30985496 DOI: 10.1097/CCO.0000000000000526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
2 Polverini PJ, D'Silva NJ, Lei YL. Precision Therapy of Head and Neck Squamous Cell Carcinoma. J Dent Res 2018;97:614-21. [PMID: 29649374 DOI: 10.1177/0022034518769645] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
3 Ku A, Kondo M, Cai Z, Meens J, Li MR, Ailles L, Reilly RM. Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab')2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab')2 - implications for a PET theranostic strategy. EJNMMI Radiopharm Chem 2021;6:25. [PMID: 34383182 DOI: 10.1186/s41181-021-00140-1] [Reference Citation Analysis]
4 De la Cruz-Concepción B, Espinoza-Rojo M, Álvarez-Fitz P, Illades-Aguiar B, Acevedo-Quiroz M, Zacapala-Gómez AE, Navarro-Tito N, Jiménez-Wences H, Torres-Rojas FI, Mendoza-Catalán MA. Cytotoxicity of Ficus Crocata Extract on Cervical Cancer Cells and Protective Effect against Hydrogen Peroxide-Induced Oxidative Stress in HaCaT Non-Tumor Cells. Plants (Basel) 2021;10:183. [PMID: 33478134 DOI: 10.3390/plants10010183] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Polverini PJ. Personalized medicine and the future of dental practice. Per Med 2018;15:449-51. [PMID: 30260289 DOI: 10.2217/pme-2018-0055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Park YP, Jin L, Bennett KB, Wang D, Fredenburg KM, Tseng JE, Chang LJ, Huang J, Chan EKL. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma. Oral Oncol 2018;78:145-50. [PMID: 29496042 DOI: 10.1016/j.oraloncology.2018.01.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
7 Bentzen JKD, Kristensen CA, Overgaard M, Rytter C, Jensen K, Hansen HS. A Non Platinum Regimen for the Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Region. Results From an Extended Phase II Study With Paclitaxel and Capecitabine. Front Oncol 2018;8:243. [PMID: 30009154 DOI: 10.3389/fonc.2018.00243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Cristina V, Herrera-Gómez RG, Szturz P, Espeli V, Siano M. Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma. Int J Mol Sci 2019;20:E5399. [PMID: 31671550 DOI: 10.3390/ijms20215399] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
9 Harrington KJ, Soulières D, Le Tourneau C, Dinis J, Licitra LF, Ahn MJ, Soria A, Machiels JH, Mach N, Mehra R, Burtness B, Ellison MC, Cheng JD, Chirovsky DR, Swaby RF, Cohen EEW. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. J Natl Cancer Inst 2021;113:171-81. [PMID: 32407532 DOI: 10.1093/jnci/djaa063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Wang H, Mustafa A, Liu S, Liu J, Lv D, Yang H, Zou J. Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. Front Pharmacol 2019;10:1254. [PMID: 31708780 DOI: 10.3389/fphar.2019.01254] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
11 Petrilli R, Eloy JO, Saggioro FP, Chesca DL, de Souza MC, Dias MVS, daSilva LLP, Lee RJ, Lopez RFV. Skin cancer treatment effectiveness is improved by iontophoresis of EGFR-targeted liposomes containing 5-FU compared with subcutaneous injection. J Control Release 2018;283:151-62. [PMID: 29864476 DOI: 10.1016/j.jconrel.2018.05.038] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
12 Shaunfield S, Yount SE, Boyken L, Agulnik M, Samant S, Cella D. Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index-10 (FHNSI-10). Health Sci Rep 2021;4:e401. [PMID: 34708159 DOI: 10.1002/hsr2.401] [Reference Citation Analysis]
13 Joseph L, C Nickel A, Patel A, F Saba N, R Leon A, F El-Chami M, M Merchant F. Incidence of Cancer Treatment Induced Arrhythmia Associated with Immune Checkpoint Inhibitors. J Atr Fibrillation 2021;13:2461. [PMID: 34950337 DOI: 10.4022/jafib.2461] [Reference Citation Analysis]
14 Rapa SF, Magliocca G, Pepe G, Amodio G, Autore G, Campiglia P, Marzocco S. Protective Effect of Pomegranate on Oxidative Stress and Inflammatory Response Induced by 5-Fluorouracil in Human Keratinocytes. Antioxidants (Basel) 2021;10:203. [PMID: 33573363 DOI: 10.3390/antiox10020203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 dos Santos Filho EX, da Silva ACG, de Ávila RI, Batista AC, Marreto RN, Lima EM, de Oliveira CMA, Mendonça EF, Valadares MC. Chemopreventive effects of FITOPROT against 5-fluorouracil-induced toxicity in HaCaT cells. Life Sciences 2018;193:300-8. [DOI: 10.1016/j.lfs.2017.09.035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
16 Willemsen ACH, Hoeben A, Lalisang RI, Van Helvoort A, Wesseling FWR, Hoebers F, Baijens LWJ, Schols AMWJ. Disease-induced and treatment-induced alterations in body composition in locally advanced head and neck squamous cell carcinoma. J Cachexia Sarcopenia Muscle 2020;11:145-59. [PMID: 31536685 DOI: 10.1002/jcsm.12487] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
17 Kuzucu İ, Baklacı D, Guler İ, Uçaryılmaz EÖ, Kum RO, Özcan M. Investigation of the Ototoxic Effect of Pembrolizumab Using a Rat Model. Cureus 2019;11:e6057. [PMID: 31827988 DOI: 10.7759/cureus.6057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Iannelli F, Zotti AI, Roca MS, Grumetti L, Lombardi R, Moccia T, Vitagliano C, Milone MR, Ciardiello C, Bruzzese F, Leone A, Cavalcanti E, De Cecio R, Iachetta G, Valiante S, Ionna F, Caponigro F, Di Gennaro E, Budillon A. Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance. Front Cell Dev Biol 2020;8:732. [PMID: 33015030 DOI: 10.3389/fcell.2020.00732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
19 Dioguardi FS, Flati V, Corsetti G, Pasini E, Romano C. Is the Response of Tumours Dependent on the Dietary Input of Some Amino Acids or Ratios among Essential and Non-Essential Amino Acids? All That Glitters Is Not Gold. Int J Mol Sci 2018;19:E3631. [PMID: 30453654 DOI: 10.3390/ijms19113631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
20 Tosoni A, Franceschi E, Pasquini E, Lanese A, Donini E, Foschini MP, Dall'olio D, Brandes AA. Immunotherapy in head and neck cancer: evidence and perspectives. Immunotherapy 2017;9:1351-8. [DOI: 10.2217/imt-2017-0125] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
21 Wolf GT, Moyer JS, Kaplan MJ, Newman JG, Egan JE, Berinstein NL, Whiteside TL. IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers. Onco Targets Ther 2018;11:3731-46. [PMID: 29988729 DOI: 10.2147/OTT.S165411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
22 Alfieri S, Cavalieri S, Licitra L. Immunotherapy for recurrent/metastatic head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2018;26:152-6. [PMID: 29432222 DOI: 10.1097/MOO.0000000000000448] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
23 Subramaniam SS, Paterson C, McCaul JA. Immunotherapy in the management of squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg 2019;57:957-66. [PMID: 31653434 DOI: 10.1016/j.bjoms.2019.08.002] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
24 Zhao J, Pan N, Huang F, Aldarouish M, Wen Z, Gao R, Zhang Y, Hu HM, Shen Y, Wang LX. Vx3-Functionalized Alumina Nanoparticles Assisted Enrichment of Ubiquitinated Proteins from Cancer Cells for Enhanced Cancer Immunotherapy. Bioconjug Chem 2018;29:786-94. [PMID: 29382195 DOI: 10.1021/acs.bioconjchem.7b00578] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
25 Kwon M, Nam GH, Jung H, Kim SA, Kim S, Choi Y, Lee YS, Cho HJ, Kim IS. Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma. Cancer Lett 2021;522:198-210. [PMID: 34571082 DOI: 10.1016/j.canlet.2021.09.029] [Reference Citation Analysis]